The Effect of Intramuscular Ventrogluteal Injection Training Given by Pecha Kucha Method

May 24, 2025 updated by: Hilal Türkben Polat, Necmettin Erbakan University

The Effect of Intramuscular Ventrogluteal Injection Training Given by Pecha Kucha Method on Nursing Students' Knowledge, Skills and Satisfaction Levels: Randomized Controlled Trial

The aim of this study is to determine the effect of intramuscular Ventrogluteal injection training given with the Pecha Kucha method on the knowledge, skill and satisfaction levels of nursing students.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Intramuscular injection is a very important intervention among basic nursing skills. Intramuscular injection technique to the ventrogluteal region is one of the safest injection techniques. In teaching this technique, both the knowledge and skills of the students can be increased by using different education methods. This research will be carried out to determine the effect of intramuscular ventrogluteal injection training given with the Pecha Kucha method on the knowledge, skill and satisfaction levels of nursing students.

Method: Data will be collected with the Introductory Information Form, Knowledge Test for Intramuscular Injection to the Ventrogluteal Region, Skill Test for Intramuscular Injection to the Ventrogluteal Region, Satisfaction Visual Analog (VAS) Scale. Data will be collected face to face between March 2025 and May 2025.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
76

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Konya, Turkey, 42000
        • Hilal Türkben Polat

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Taking the Fundamentals of Nursing course for the first time
  • Being between the ages of 18-25
  • Students who can speak and understand Turkish fluently.
  • Students who accept to participate in the study voluntarily.

Exclusion Criteria:

  • Students who have previously taken the Fundamentals of Nursing 1st year course.
  • Students who are graduates of Health Vocational High School.
  • Students who have transferred to the nursing department with the vertical transfer exam.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Experimental group (Pecha Kucha training)
Students will be given training on intramuscular injection for the Ventrogluteal region(VGR) using the Pecha Kucha training method. The 20-slide powerpoint presentation will last approximately 7 minutes. After the training, students will ; Complete the Knowledge Test for Intramuscular Injection to the VGR( 15 minutes after training). Students will complete the satisfaction scale after the training(15 minutes after training) . Afterwards, students will be taken to the Nursing Skills laboratory and will perform VG injection on a low-level intramuscular injection simulator(2 hour after training). The Skill Test for Intramuscular Injection to the VGR will be completed by an independent observer who is not a researcher while the student is performing the VG injection on simulator. Students' knowledge, skills and satisfaction will be measured again 30 days after the training with the same measurement tools.
Other: Experimental group (Pecha Kucha training)
Ventrogluteal injection training given to students using the Pecha Kucha training method
No Intervention: Control group (Standard Training Method)
Students assigned to the control group will be given intramuscular injection training for the Ventrogluteal region(VGR) with the Standard training method. The 30-slide powerpoint presentation will last approximately 20 minutes. After the training, students will ; Complete the Knowledge Test for Intramuscular Injection to the VGR( 15 minutes after training). Students will complete the satisfaction scale after the training(15 minutes after training) . Afterwards, students will be taken to the Nursing Skills laboratory and will perform VG injection on a low-level intramuscular injection simulator(2 hour after training). The Skill Test for Intramuscular Injection to the VGR will be completed by an independent observer who is not a researcher while the student is performing the VG injection on simulator. Students' knowledge, skills and satisfaction will be measured again 30 days after the training with the same measurement tools.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Knowledge Test for Intramuscular Injection to the Ventrogluteal Region
Time Frame: 15 minutes after training, 1 month after training
It is a test with 24 propositions about VG injection. Propositions are answered as true, false and I have no idea. 1 point is given for each correct answer. The form was developed by the research team
15 minutes after training, 1 month after training

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Skill Test for Intramuscular Injection to the Ventrogluteal Region
Time Frame: 2 hours later after training, 1 month after training
It was prepared to measure the skill levels of students regarding VG injection application. It is a test that includes 33 application steps about VG injection and is evaluated out of 100 points in total. The student who performs each application step receives the score given in the test in return. The test is evaluated based on the total score. The form was developed by the research team
2 hours later after training, 1 month after training
Satisfaction Visual Analog (VAS) Scale:
Time Frame: 15 minutes after training
The scale consists of a horizontal or vertical line, scaled as 10 cm/100 mm. In this study, a form scored between 0-10 points in the horizontal feature will be used. In the satisfaction assessment, a score of 0 on the scale indicates no satisfaction, and a score of 10 indicates very satisfied
15 minutes after training

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Necmettin Erbakan University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 4, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 4, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 4, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 17, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 17, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 21, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 30, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 24, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NEU-SKASBF-HTP-02

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings